One of the candidates included in the deal has already shown promise in a phase 1a advanced breast cancer study ...

Many initiatives have tried to address this partnership challenge: the Healthcare Communications Association’s (HCA) own ...

Medscape wants to take the opportunity to look back and recap what was accomplished at ESC 2024. At this year’s event, ...

NHS England has announced that hundreds of babies have begun to be tested for over 200 genetic conditions as part of a study led by Genomics England. The Generation Study is evaluating the potential ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) as an add-on maintenance treatment for chronic obstructive pulmonary disease (COPD). The ...

The fourth annual QiC Dermatology Awards took place in Reading earlier this month and results can be found online here: QiC Dermatology 2024 Results – Quality in Care Awards Programme. NHS teams from ...

Eli Lilly has announced that it is investing $4.5bn into a new US facility for advanced manufacturing and drug development. The Lilly Medicine Foundry will give the company the ability to research new ...

Astellas Pharma’s claudin 18.2-directed cytolytic antibody has been approved by the European Commission (EC) as part of a first-line combination treatment for a subset of gastric cancer patients.

UCB has shared positive two-year results for its inflammatory disease drug Bimzelx (bimekizumab) in moderate-to-severe hidradenitis suppurativa (HS). New data from the phase 3 BE HEARD I and BE HEARD ...

Johnson & Johnson’s (J&J) Yuvanci (single tablet combination therapy [STCT] of macitentan and tadalafi) has been approved by the European Commission (EC) as a long-term treatment for pulmonary ...

Roche’s injectable component C5 inhibitor has been recommended by the National Institute for Health and Care Excellence (NICE) to treat the rare blood disorder paroxysmal nocturnal haemoglobinuria ...

The US Food and Drug Administration (FDA) has granted rare paediatric disease (RPD) designation to Enterprise Therapeutics’ investigational cystic fibrosis therapy. Estimated to affect more than ...